Angany Inc. (Canada)

ANGANY is a privately-held, clinical-stage pharmaceutical company based in Lévis, Quebec, Canada, dedicated to developing a new, sustainable and curative approach for people suffering from allergic asthma. The company describes itself as developing next-generation biologics designed to transform the lives of people suffering from allergic asthma and other immune-mediated diseases. Its therapeutic strategy is not merely to control symptoms but to reverse the underlying cause of allergy by restoring immune tolerance to the specific allergen involved. ANGANY's platform is built on synthetic biology. The company has developed a proprietary self-adjuvant vector called the eBioparticle™, which has demonstrated at the preclinical level the possibility of reversing the allergic dynamics at the root of allergic asthma. An initial clinical study conducted at Imperial College London confirmed the product's safety and hypoallergenicity, which the company presents as a break with existing immunotherapy products. In addition to its therapeutic platform, ANGANY has developed a third-generation plant production platform that is described as flexible, fast and easy to scale up. The company states that its work draws on 30 years of research in biotechnology, immunology and vaccinology, and more than $30 million in R&D investments. It is developing a simple-to-administer form of immunotherapy. ANGANY positions its approach against the limitations of currently available options for allergic asthma sufferers, which it characterizes as either symptomatic remedies or demanding desensitization treatments. The company frames its mission around the considerable unmet need in allergy and allergic asthma, citing projections that allergy could affect approximately 50% of the population by 2050 and that the number of people diagnosed with allergy in the United States alone will increase by more than a million a year by 2060. ANGANY operates as a private company and is not publicly listed. Its activities span research and development in Canada, with clinical work referenced in the United Kingdom and a focus on the United States market context in its communications. The company's public identity is centered on its eBioparticle™ platform and its ambition to provide a curative, rather than merely symptomatic, solution for allergic asthma.

ANGANY is a privately-held, clinical-stage pharmaceutical company based in Lévis, Quebec, Canada. The company has built its identity around the development of next-generation biologics for allergic asthma and other immune-mediated diseases. According to its own account, its therapeutic approach is backed by 30 years of research in biotechnology, immunology and vaccinology, and by more than $30 million in R&D investments. The central element of ANGANY's history is the creation and development of its exclusive therapeutic platform based on synthetic biology. This platform centers on a self-adjuvant vector called the eBioparticle™. At the preclinical level, the eBioparticle™ demonstrated the possibility of reversing the allergic dynamics at the root of allergic asthma. This represented a departure from conventional immunotherapy, which the company characterizes as either symptomatic or demanding desensitization. A significant milestone in the company's development was an initial clinical study conducted at Imperial College London. This study confirmed the safety and hypoallergenicity of the product, which ANGANY describes as marking a break with existing immunotherapy products. In parallel, ANGANY developed a third-generation plant production platform, described as flexible, fast and easy to scale up, intended to support sustainable production of its therapies. The company's stated aim is to provide sustainable solutions in a context where allergy sufferers often still rely on medication that merely alleviates symptoms. ANGANY has developed a simple-to-administer form of immunotherapy. Its public communications emphasize the growing burden of allergic asthma and allergy, citing that asthma affects some 262 million people worldwide and that allergy is a chronic, progressive disease. The company positions its work as addressing a considerable unmet need, with the ambition of restoring immune tolerance to the allergen in question and thereby controlling allergic asthma. As of its public disclosures, ANGANY remains a private, clinical-stage company. It has not been publicly listed, and no parent company or owner is identified in the available evidence. Its headquarters is in Lévis, Canada, while its clinical study was conducted in the United Kingdom, and its market commentary frequently references the United States.

• ANGANY develops its exclusive therapeutic platform based on synthetic biology, centered on the self-adjuvant eBioparticle™ vector.

• Preclinical studies demonstrate the possibility of reversing the allergic dynamics at the root of allergic asthma using the eBioparticle™ platform.

• An initial clinical study at Imperial College London confirms the product's safety and hypoallergenicity.

• ANGANY develops a third-generation plant production platform described as flexible, fast and easy to scale up.

A privately-held, clinical-stage pharmaceutical company developing a curative, next-generation biologic approach to allergic asthma by restoring immune tolerance, positioned against symptomatic remedies and demanding desensitization treatments.

• eBioparticle™ platform

  A self-adjuvant vector based on synthetic biology, developed as the core of ANGANY's immunotherapy for allergic asthma.

• Next-generation biologics for allergic asthma

  Biologics under development offering the prospect of safety and efficacy in treating allergic asthma by restoring immune tolerance.

• Third-generation plant production platform

  A flexible, fast and easy-to-scale-up production platform developed by ANGANY.

1. 1Home | ANGANYangany.com
2. 2About ANGANY | ANGANYangany.com
3. 3About Allergy | ANGANYangany.com
4. 4Angany Inc. (Canada) - Wikidatawikidata.org